Brief: Achieve Life Sciences Says Last Subject Completes Phase 3 ORCA-3 Trial
29/03/2023 13:06
March 29 (Reuters) - Achieve Life Sciences Inc ACHV.O :
* ACHIEVE LIFE SCIENCES ANNOUNCES LAST SUBJECT LAST VISIT
COMPLETED IN PHASE 3 ORCA-3 TRIAL OF CYTISINICLINE FOR SMOKING
CESSATION
Source text for Eikon: ID:nGNEBG987
Further company coverage: ACHV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achieve Life Sciences
See all newsAchieve Life Sciences Q3 net loss and loss per share beat estimates
Brief: Achieve Life Sciences Presents 52-Week Cytisinicline Results For Smoking And Vaping Cessation At Chest 2026
Brief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Achieve Life Sciences Appoints Kaitlyn Tuson As Senior Vice President, Marketing And Communications
Brief: Achieve Life Sciences - Enters ATM Sale Agreement With Jefferies For Up To $150 Million In Common Stock